Marvel Biosciences Achieves CGMP Milestone and Begins IND-Enabling Pre-Clinical Toxicology Testing of Lead Compound

Dec 8, 2021 | News

Calgary, Alberta–(Newsfile Corp. – December 8, 2021) – Marvel Biosciences Corp. (TSXV: MRVL) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the “Company” or “Marvel”), is pleased to announce that it...

Marvel Biosciences Talks “Drug Redevelopment” Approach, Transitioning from Pre-Clinical to Clinical

Dec 4, 2021 | News

https://www.youtube.com/watch?v=NPEjfyWW7Zg...

Marvel Biosciences to Host Investor Webinar

Nov 29, 2021 | News

Calgary, Alberta–(Newsfile Corp. – November 29, 2021) – Marvel Biosciences Corp. (TSXV: MRVL) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the”Company” or “Marvel”), is pleased to announce that it...

Marvel Biosciences Lead Asset MB-204 Show 47% Reduction in Liver Fibrosis and Active Indications in Multiple Pre-Clinical Models of Nash

Nov 23, 2021 | News

Calgary, Alberta–(Newsfile Corp. – November 23, 2021) – Marvel Biosciences Corp. (TSXV: MRVL) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the “Company” or “Marvel”), today announced that it has...

Marvel Biosciences Announces New Program to Develop Novel Orally Dosed Non-Hallucinogenic Neuroplastic Promoting Compounds

Oct 27, 2021 | News

Calgary, Alberta–(Newsfile Corp. – October 27, 2021) – Marvel Biosciences Corp. (TSXV: MRVL) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the “Company” or “Marvel”), is pleased to announce that the...

Marvel Biosciences Provides Updates on the Status of Its MB-204 Manufacturing Efforts and Sets Out Future Milestones

Oct 15, 2021 | News

Calgary, Alberta–(Newsfile Corp. – October 15, 2021) – Marvel Biosciences Corp. (TSXV: MRVL) and its wholly owned subsidiary, Marvel Biotechnology Inc.(collectively the”Company”or”Marvel”), is pleased to announce that as a...